2026-02-10 17:40:16
Latest Post
UVS Hospitality and Services Ltd announces strategic fundraise and acquisition of Calcio Restaurants in major Expansion Move
Cholamandalam Financial Holdings Ltd 9M FY26 consolidated PAT at Rs. 3860 crores
Strategic Boost to Atmanirbharta in Shipbuilding as GRSE and HSL Sign MoU
India needs nearly 2,000 Exploration Licenses in oil and gas to become energy secured says, Vedanta Group Chairman
Nifty steadies after gap-up, recovery attempts gain traction
Stock Report
Ranbaxy Laboratories Q3 PAT up 651% at Rs.1404 million, global sales at 16404 million
Posted On : 2006-10-19 07:24:45( TIMEZONE : IST )
Ranbaxy Laboratories Ltd has announced the following Unaudited results for the quarter ended September 30, 2006:
The Company has posted a profit after tax of Rs 973.10 million for the quarter ended September 30, 2006 as compared to net loss of Rs 107.70 million for the quarter ended September 30, 2005. Total Income (net of excise) has increased from Rs 8816.40 million for the quarter ended September 30, 2005 to Rs 10712.20 million for the quarter ended September 30, 2006.
The Consolidated results are as follows:
The Group has posted a profit after tax & Minority Interests of Rs 1393.00 million for the quarter ended September 30, 2006 as compared to Rs 184.00 million for the quarter ended September 30, 2005. Total Income (net of excise) has increased from Rs 13633.00 million for the quarter ended September 30, 2005 to Rs 16154.00 million for the quarter ended September 30, 2006.
The Board of Directors has approved payment of Interim Dividend of 50% (@ Re 2.50 per share of par value of Rs 5 each) for the year ending December 31, 2006.
Further the Company has informed that, November 03, 2006 has been fixed as the Record Date for the purpose of payment of interim dividend. Interim Dividend will be paid to the eligible shareholders on or before November 14, 2006.
